Literature DB >> 9933083

Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor.

R Dyall1, L V Vasovic, R A Clynes, J Nikolić-Zugić.   

Abstract

Following subcutaneous implantation, the murine lymphoma E.G7 [a variant of EL-4, transfected with the chicken ovalbumin (OVA) gene] up-regulates the CD4 molecule. We previously showed that the administration of an anti-CD4 monoclonal antibody (mAb) to EG.7-bearing mice leads to a rapid and complete regression of large established tumors. This tumor regression was shown to require both CD8+ cells and functional Fcgamma receptors (FcgammaR), as it failed to occur in mice depleted of CD8 cells, or mice genetically deficient in FcgammaI/III (gamma-/-mice). Using adoptive transfer, we now show that the FcgammaR+ cells required for this regression are the CD11b+ (phagocytic) cells. Furthermore, experiments using peptide tolerization demonstrated that the critical CD8 CTL population in this model is tumor specific. Analysis of tumors at various stages of regression revealed a massive CD11b+FcgammaR+ and a marginal CD8 infiltration. In the presence of the CTL determinant OVA-8 on tumor cells and of the antitumor mAb, this CD8 infiltration became remarkable, and correlated with tumor regression. These results identify the specific cellular effectors essential for the mAb-mediated tumor regression, and suggest that FcgammaR-activated macrophages induced an expansion of tumor-eliminating CTL in situ.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933083     DOI: 10.1002/(SICI)1521-4141(199901)29:01<30::AID-IMMU30>3.0.CO;2-D

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Authors:  Natalie A Bezman; Amy Jhatakia; Alper Y Kearney; Ty Brender; Mark Maurer; Karla Henning; Misty R Jenkins; Amy J Rogers; Paul J Neeson; Alan J Korman; Michael D Robbins; Robert F Graziano
Journal:  Blood Adv       Date:  2017-05-08

3.  Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

Authors:  Adam M Boruchov; Glenn Heller; Maria-Concetta Veri; Ezio Bonvini; Jeffrey V Ravetch; James W Young
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

4.  Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

5.  Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

Authors:  Thomas F Tedder; Aris Baras; Yan Xiu
Journal:  Springer Semin Immunopathol       Date:  2006-11-08

6.  Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Authors:  Kory L Alderson; Mitchell Luangrath; Megan M Elsenheimer; Stephen D Gillies; Fariba Navid; Alexander L Rakhmilevich; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-11-15       Impact factor: 6.968

7.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Authors:  Danila Valmori; Naira E Souleimanian; Valeria Tosello; Nina Bhardwaj; Sylvia Adams; David O'Neill; Anna Pavlick; Juliet B Escalon; Crystal M Cruz; Angelica Angiulli; Francesca Angiulli; Gregory Mears; Susan M Vogel; Linda Pan; Achim A Jungbluth; Eric W Hoffmann; Ralph Venhaus; Gerd Ritter; Lloyd J Old; Maha Ayyoub
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

Review 8.  Immunological ignorance of solid tumors.

Authors:  Adrian F Ochsenbein
Journal:  Springer Semin Immunopathol       Date:  2005-01-27

9.  Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.

Authors:  Kavita M Dhodapkar; Joseph Krasovsky; Barbara Williamson; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

10.  The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.

Authors:  Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder
Journal:  J Exp Med       Date:  2004-06-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.